Vamikibart Shows Early Safety in Uveitic Macular Edema - Top-Institutions - MDSpire

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

  • By

  • Kerri Miller

  • May 7, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute
    Bascom Palmer Eye Institute

    Miami, FL

    Key Differentiators

    • Ophthalmology

  • #2

    University of Miami Miller School of Medicine
    University of Miami Miller School of Medicine

    Miami, FL

    Key Differentiators

    • Ophthalmology

  • #3

    Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical School

    New Brunswick, NJ

    Key Differentiators

    • Ophthalmology

  • #4

    UCSF Medical Center
    UCSF Medical Center

    San Francisco, CA

    Key Differentiators

    • Ophthalmology

  • #5

    Flaum Eye Institute, University of Rochester
    Flaum Eye Institute, University of Rochester

    Rochester, NY

    Key Differentiators

    • Ophthalmology

Original Source(s)

Vamikibart Shows Early Safety in Uveitic Macular Edema

  • by Kerri Miller

  • May 7, 2026

Related Content

Smoking Doubles Risk of Vision Loss

New research indicates smoking doubles the risk of multiple sight-threatening conditions

  • May 15, 2026

  • 3 min
2026 Retina World Congress Preview

Baruch D. Kuppermann, MD, PhD, highlights the global focus and broad retina agenda of the upcoming Retina World Congress meeting in Fort Lauderdale.

Late-onset bullous keratopathy after iris-fixated phakic intraocular lens implantation: a case report